The Generics Bulletin Podcast: Recent And Upcoming Industry Events

Our Editorial Team Discusses Conferences From Recent Months Through Into Early 2025

Generics Bulletin’s editorial team discusses recent conferences held by Medicines for Europe and the AAM, while looking ahead to the key off-patent industry events that are on the calendar over the next few months and beyond.

Generic Bulletin Podcast

This edition of the Generics Bulletin podcast sees editor Dave Wallace, deputy editor Dean Rudge and reporters Urtė Fultinavičiūtė and Adam Zamecnik discuss recent off-patent industry events such as the legal and annual conferences held by Medicines for Europe in Dublin in June and the annual meeting of the US Association for Accessible Medicines earlier this year, while also looking ahead to the key off-patent industry events on the calendar over the next few months and beyond.

Citeline · The Generics Bulletin Podcast: Recent And Upcoming Industry Events

Open Media

Generics Bulletin reported on Medicines for Europe’s June conferences in a series of articles published earlier this year. (Also see "Medicines For Europe Highlights Sector Challenges As It Celebrates Milestone Anniversary" - Generics Bulletin, 17 June, 2024.)

This included a detailed report on the concluding panel of industry leaders. (Also see "The View From The Top: European CEOs Highlight Industry Priorities" - Generics Bulletin, 27 June, 2024.)

We also previously brought you coverage from the AAM’s annual conference, including an interview with chair Keren Haruvi. (Also see "‘Is The Market Now Sustainable? The Answer Is Still Not’: AAM’s Haruvi On The Need To Fix The US Generics Industry" - Generics Bulletin, 13 February, 2024.)

The AAM event also closed with a leaders’ panel. (Also see "The Long Read: CEOs Unplug At AAM Conference" - Generics Bulletin, 15 February, 2024.)

More from Generics

Spanish Authorities Investigate Sandoz Over Information-Sharing

 
• By 

Spanish competition regulator the CNMC has announced an investigation into Sandoz and its Bexal subsidiary – as well as Alliance Healthcare España and Bluetab Solutions – over sharing sensitive commercial information relating to pharmacy orders for generics.

Meitheal Adds To US Liraglutide List As It Looks To Ease Shortage Concerns

 
• By 

Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.

Glenmark Dodges UK Dapagliflozin Injunction Ahead Of Patent Trial Decision

 
• By 

A UK High Court justice came down on the side of Glenmark in AstraZeneca’s bid to enjoin the firm from launching a generic version of its Forxiga blockbuster before judgment is delivered in the firms’ patent-litigation clash.

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By 

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.

More from Conferences

IGBA’s Susana Almeida On Consensus Building, Harmonization, And Policy Built On Science – Not Politics

 

IGBA secretary general Susana Almeida takes Generics Bulletin through an almost two-decade journey of developing global regulatory convergence and the next goals for the off-patent industry.

After A Decade Of US Biosimilars, ‘The Challenges Are Becoming More Clear’

 
• By 

As the US marks 10 years since the first biosimilar approval and launch, AAM Biosimilars Council executive director Craig Burton talks to Generics Bulletin about the lessons learned so far and the path ahead, including how to move on from market models that have proved to be “not appropriate” for biosimilars.

In Discussion With Medicines For Europe: Bracing For US Tariffs And Embracing Ukraine

 

Tariffs, international cooperation, and war: the off-patent industry is not immune to the political issues raging across the globe. Medicines for Europe’s Adrian van den Hoven and Beata Stepniewska spoke with Generics Bulletin about what these developments mean for the sector.